Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)

Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) at other companies

Eli Lilly logo
Eli LillyLLY
——

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
MoonLake Immunotherapeutics (MLTX) reported other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) of $5.76M in Q1 2026.
How has MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) changed year-over-year?
MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) increased by 92.9% year-over-year, from $2.99M to $5.76M.
What is the long-term trend for MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) has grown at a 139.2% compound annual growth rate (CAGR), from $148.77K to $4.87M.